Publications by authors named "Hope Rugo"

Claim this Profile
R
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.
Hope S Rugo, Virginia Kaklamani, Heather McArthur, Seth A Wander, William Gradishar

Clin Cancer Res· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RISE UP for breast cancer 2024: conference highlights & takeaways.
Taylor Glatt, Katherine Leggat-Barr, Nandini Seth, Diane Heditsian, Laura van 't Veer, Hope Rugo

Breast Cancer Res Treat· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Shanu Modi, William Jacot, Hiroji Iwata, Yeon Hee Park, Maria Vidal Losada, Hope S Rugo

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing awareness of and referral to support services in advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 7).
Belinda Kiely, Luzia Travado, Andrea L Smith, Isabelle Aloi Timeus, Sung-Bae Kim, Hope Rugo

Breast· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies.
Yeon Hee Park, Javier Cortes, Shanu Modi, Sara A Hurvitz, Giampaolo Bianchini, Hope S Rugo

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer.
Saya Jacob, Samantha Fisch, Carolyne Face, Kelly Blum, Madhuri Chengappa, Hope S Rugo

NPJ Breast Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting.
Neel D Pasricha, Stella K Kim, Asim V Farooq, Ethan S Lindgren, Rongshan Yan, Hope S Rugo

JAMA Ophthalmol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion.
Neil M Iyengar, Joyce A O'Shaughnessy, Heather B Moore, Erika Hamilton, Komal L Jhaveri, Hope S Rugo

NPJ Breast Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.
Mark Jesus M Magbanua, Nayelis A Manon, Denise M Wolf, Samuel Rivero-Hinojosa, Ziad Ahmed, Hope S Rugo

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy.
Hope S Rugo, David W Cescon, Mark E Robson, Seock-Ah Im, Florence Dalenc

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical perspective on management of key adverse events with sacituzumab govitecan.
Sara M Tolaney, Guru P Sonpavde, Paolo Tarantino, Maryam B Lustberg, Hope S Rugo

Oncologist· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
François-Clément Bidard, Grégoire Gessain, Thomas Bachelot, Lucie Frechin, Anne Vincent-Salomon, Hope S Rugo

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer.
Richard S Finn, Hope S Rugo, Javier Cortes, Sibylle Loibl, Grace Foley

Target Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Hope S Rugo

J Natl Compr Canc Netw· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer.
Laura A Huppert, Amelia S Gliwa, Madeline Tait, Laura Quintal, Stephanie Starzinski, Hope S Rugo

NPJ Breast Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Robert Wesolowski, Hope S Rugo, Jennifer M Specht, Hyo S Han, Peter Kabos

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
François-Clément Bidard, Grégoire Gessain, Thomas Bachelot, Lucie Frechin, Anne Vincent-Salomon, Hope S Rugo

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
Julie Van Hassel, Katrina Dimitroff, Christina Yau, Rita Mukhtar, Judy C Boughey, Hope Rugo

Ann Surg Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study.
Nira A Krasnow, Michelle Jayaraj, Mia Salans, Kelsey Kuwahara, Maggie H Zhou, Hope S Rugo

Breast Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting.
Rudolph M Navari, Timothy Tyler, Naoki Inui, Hirotoshi Iihara, Erminio Bonizzoni, Hope S Rugo

Future Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.
Francesco Schettini, Sabrina Nucera, Giuseppe Di Grazia, Fabiola Giudici, Carla Strina, Hope S Rugo

JNCI Cancer Spectr· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Germline and Somatic Mutations in Breast Cancer Treatment Strategies.
Eric Hahnen, Jan Hauke, Karen Gelmon, Frederik Marmé, Corinna Ernst, Hope S Rugo

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan.
Hope Rugo, Aditya Bardia, Debora S Bruno, Vinicius Ernani, Erika Hamilton

Support Care Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis.
Jeremy Williams, Roman Camarda, Serghei Malkov, Lisa J Zimmerman, Suzanne Manning, Hope S Rugo

Nat Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing.
Chiara Corti, Hope S Rugo, Sara M Tolaney

Am Soc Clin Oncol Educ Book· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis